Literature DB >> 31197743

Regenerative potential of platelets in patients with chronic kidney disease.

Elżbieta Cecerska-Heryć1, Rafał Heryć2, Magda Wiśniewska2, Anna Michalczyk3, Barbara Dołęgowska4.   

Abstract

INTRODUCTION: Chronic kidney disease (CKD) is a systemic disease affecting many organs. Progression of renal failure aggravates ongoing inflammation and increases oxidative stress. In the final stage of CKD, it is necessary to use renal replacement therapy. A side effect of dialysis therapy is the synthesis of proinflammatory factors and increased oxidative stress, which activates platelets and immune cells. AIM OF THE STUDY: To determine the regenerative potential of platelets in patients with CKD based on the analysis of the relationships between substances with potential regenerative action, as well as analysis of the influence of the type of renal replacement therapy used on regeneration of platelets.
MATERIALS AND METHODS: The study group consisted of 117 patients. Based on the type of therapy used, patients were divided into four groups: hemodialysis, peritoneal dialysis, kidney transplant patients, and conservative treatment (30, 30, 27, and 30 patients). The control group consisted of 30 healthy volunteers. The concentrations of IGF-1, TGF-β, and PDGF-B in the blood serum were measured by ELISA methods.
RESULTS: It was shown that renal replacement therapy significantly influences the concentration of platelet growth factors (IGF-1: p = 0.025 and PDGF-B: p = 0.012). There was a relationship between the type of renal replacement therapy and the duration of dialysis, and the concentration of IGF-1, PDGF-B (p < 0.00001, p < 0.001).
CONCLUSIONS: The type of renal replacement therapy has a different effect on the concentration of platelet-derived growth factors IGF-1 and PDGF-B. PD patients had the highest concentrations of all growth factors, and this may be due to the presence of inflammation induced by dialysis-related advanced end-products of glycosylation (AGE).

Entities:  

Keywords:  Chronic kidney disease; IGF-1; PDGF-B; Platelet growth factors; TGF-β

Mesh:

Year:  2019        PMID: 31197743     DOI: 10.1007/s11255-019-02190-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  49 in total

1.  Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions.

Authors:  H B Lowman; Y M Chen; N J Skelton; D L Mortensen; E E Tomlinson; M D Sadick; I C Robinson; R G Clark
Journal:  Biochemistry       Date:  1998-06-23       Impact factor: 3.162

2.  Renal TGF-beta in HIV-associated kidney diseases.

Authors:  I Bódi; P L Kimmel; A A Abraham; L P Svetkey; P E Klotman; J B Kopp
Journal:  Kidney Int       Date:  1997-05       Impact factor: 10.612

Review 3.  TGF-beta signaling in renal disease.

Authors:  Erwin P Böttinger; Markus Bitzer
Journal:  J Am Soc Nephrol       Date:  2002-10       Impact factor: 10.121

4.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.

Authors:  T Yamamoto; T Nakamura; N A Noble; E Ruoslahti; W A Border
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

5.  Regulation of growth hormone (GH), insulin-like growth factor (IGF)I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis.

Authors:  J Kratzsch; W F Blum; E Schenker; E Keller
Journal:  Exp Clin Endocrinol Diabetes       Date:  1995       Impact factor: 2.949

6.  Oxidative stress, inflammation and early cardiovascular damage in children with chronic renal failure.

Authors:  Aydin Ece; Fuat Gürkan; Mehmet Kervancioğlu; Halil Kocamaz; Ali Güneş; Yildiz Atamer; Sahbettin Selek
Journal:  Pediatr Nephrol       Date:  2006-03-07       Impact factor: 3.714

7.  Chronic kidney disease alters vascular smooth muscle cell phenotype.

Authors:  M Alexandra Monroy; Jianhua Fang; Shan Li; Lucas Ferrer; Mark P Birkenbach; Iris J Lee; Hong Wang; Xiao-Feng Yang; Eric T Choi
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

8.  Platelet-rich plasma peptides: key for regeneration.

Authors:  Dolores Javier Sánchez-González; Enrique Méndez-Bolaina; Nayeli Isabel Trejo-Bahena
Journal:  Int J Pept       Date:  2012-02-22

9.  A cohort study of insulin-like growth factor 1 and mortality in haemodialysis patients.

Authors:  Erik Nilsson; Juan Jesus Carrero; Olof Heimbürger; Olof Hellberg; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin Kidney J       Date:  2015-11-26

10.  Elevated expression levels of serum insulin-like growth factor-1, tumor necrosis factor-α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy.

Authors:  Xiang Li; Ting-Ting Wu; Juan Chen; Wen Qiu
Journal:  J Diabetes Investig       Date:  2016-07-15       Impact factor: 4.232

View more
  1 in total

1.  Effect of renal replacement therapy on selected arachidonic acid derivatives concentration.

Authors:  Elżbieta Cecerska-Heryć; Rafał Heryć; Magda Wiśniewska; Natalia Serwin; Bartłomiej Grygorcewicz; Barbara Dołęgowska
Journal:  BMC Nephrol       Date:  2020-09-11       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.